<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00974324</url>
  </required_header>
  <id_info>
    <org_study_id>PTCL0908</org_study_id>
    <nct_id>NCT00974324</nct_id>
  </id_info>
  <brief_title>Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma</brief_title>
  <acronym>PTCL</acronym>
  <official_title>Phase 2 Study of Endostar Combined With CHOP Regimen as the First Line Chemotherapy for Untreated Peripheral T Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of angiogenesis has been less clear in lymphoma than in solid tumors, in part&#xD;
      related to the heterogeneity of disease and technical issues. In addition to vascular&#xD;
      endothelial growth factor (VEGF) effects on angiogenesis and the integrity of tumor&#xD;
      vasculature, autocrine VEGF-receptor (VEGF-R)-mediated signaling may play a role in lymphoma.&#xD;
      Microvessel density, a measure of angiogenesis, is highest in peripheral T-cell lymphomas&#xD;
      (PTCL), followed by diffuse large B-cell (DLBCL) and intra-follicular follicular lymphoma&#xD;
      (FL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate efficacy and safety of endostar combined with CHOP regimen as first line&#xD;
      treatment for peripheral T cell lymphoma.The second subject is to clarify the association&#xD;
      between expression of VEGF and prognosis in peripheral T cell lymphoma,unspecified(PTCL-U)&#xD;
      and angioimmunoblastic T-cellLymphoma(AILT).Methods 15 cases of PTCL were enrolled in this&#xD;
      study.Immunohistochemical staining was performed by EnVision method using antibodies VEGF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy include overall response rate, disease free survival and overall survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety of endostar combined with CHOP</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>T Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>endostar combined with CHOP regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>endostar and CHOP</intervention_name>
    <description>endostar, 7.5m g/m2, intravenous, Day 2-15, repeat every 3 weeks&#xD;
CHOP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone</description>
    <arm_group_label>treatment</arm_group_label>
    <other_name>endostar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Disease Characteristics:&#xD;
&#xD;
               -  Diagnosis of peripheral T-cell:&#xD;
&#xD;
                    -  Any stage disease allowed&#xD;
&#xD;
               -  At least 1 objective measurable disease parameter&#xD;
&#xD;
               -  No anaplastic lymphoma kinase (ALK)-positive T-cell large cell lymphoma&#xD;
&#xD;
                    -  ALK-negative T-cell large cell lymphoma allowed&#xD;
&#xD;
               -  No cutaneous T-cell lymphoma&#xD;
&#xD;
                    -  No sezary syndrome&#xD;
&#xD;
                    -  No NK/T cell lymphoma&#xD;
&#xD;
               -  No history of or current radiographic evidence of CNS metastasis, including&#xD;
                  previously treated, resected, or asymptomatic brain lesions or leptomeningeal&#xD;
                  involvement&#xD;
&#xD;
          -  Patient Characteristics:&#xD;
&#xD;
               -  Age:&#xD;
&#xD;
                    -  18 -75 years&#xD;
&#xD;
               -  Performance status:&#xD;
&#xD;
                    -  ECOG 0-2&#xD;
&#xD;
               -  Life expectancy:&#xD;
&#xD;
                    -  No less than 12 weeks&#xD;
&#xD;
               -  Hematopoietic:&#xD;
&#xD;
                    -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
                    -  Hemoglobulin ≥ 80*10^12/L&#xD;
&#xD;
                    -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
                    -  No evidence of bleeding diathesis or coagulopathy&#xD;
&#xD;
               -  Hepatic:&#xD;
&#xD;
                    -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
                    -  AST ≤ 2.5 times ULN&#xD;
&#xD;
                    -  PT, INR, and PTT ≤ 1.5 times normal&#xD;
&#xD;
               -  Renal:&#xD;
&#xD;
                    -  Creatinine ≤ 1.5 times normal&#xD;
&#xD;
               -  Cardiovascular:&#xD;
&#xD;
                    -  No cerebrovascular accident within the past 6 months&#xD;
&#xD;
                    -  No myocardial infarction within the past 6 months&#xD;
&#xD;
                    -  No unstable angina within the past 6 months&#xD;
&#xD;
                    -  No New York Heart Association class II-IV congestive heart failure&#xD;
&#xD;
                    -  No uncontrolled hypertension (i.e., systolic blood pressure [BP] &gt; 150 mm Hg&#xD;
                       or diastolic BP &gt; 100 mm Hg)&#xD;
&#xD;
                    -  No other clinically significant cardiovascular or peripheral vascular&#xD;
                       disease&#xD;
&#xD;
                    -  LVEF is normal&#xD;
&#xD;
               -  Other:&#xD;
&#xD;
                    -  Not pregnant or nursing&#xD;
&#xD;
                    -  Fertile patients must use effective contraception&#xD;
&#xD;
                    -  No history of active seizures&#xD;
&#xD;
                    -  No non-healing ulcer (unless involved with lymphoma)&#xD;
&#xD;
                    -  No active infection requiring parenteral antibiotics&#xD;
&#xD;
                    -  No known HIV positivity&#xD;
&#xD;
                    -  No other active malignancy within the past 6 months except carcinoma in situ&#xD;
                       of the cervix or basal cell carcinoma of the skin&#xD;
&#xD;
          -  PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
               -  Biologic therapy:&#xD;
&#xD;
                    -  Not specified&#xD;
&#xD;
               -  Chemotherapy:&#xD;
&#xD;
                    -  No prior chemotherapy was allowed&#xD;
&#xD;
               -  Surgery:&#xD;
&#xD;
                    -  More than 4 weeks since prior major invasive surgery or open biopsy&#xD;
&#xD;
                    -  At least 7 days since prior minor surgery&#xD;
&#xD;
                    -  No concurrent major surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment included chemotherapy and radiotherapy&#xD;
&#xD;
          -  With the following risk factors: Uncontrolled or severe cardiovascular disease (e.g.,&#xD;
             myocardial infarction within the past 6 months, congestive heart failure treated with&#xD;
             medications, or uncontrolled hypertension)&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  Other currently active malignancy except nonmelanoma skin cancer&#xD;
&#xD;
          -  Uncontrolled or severe bleeding,diarrhea,intestinal obstruction&#xD;
&#xD;
          -  Hypersensitivity to albumen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junning Cao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Member of Fudan University Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haiyi Guo, MD</last_name>
    <phone>86(021)64175590</phone>
    <phone_ext>5008</phone_ext>
    <email>guohaiyi@csco.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haiyi Guo, MD</last_name>
      <phone>86(021)64175590</phone>
      <phone_ext>5008</phone_ext>
      <email>guohaiyi@csco.org.cn</email>
    </contact>
    <investigator>
      <last_name>Haiyi Guo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Junning Cao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>September 9, 2009</study_first_submitted>
  <study_first_submitted_qc>September 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2009</study_first_posted>
  <last_update_submitted>September 14, 2010</last_update_submitted>
  <last_update_submitted_qc>September 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Haiyi Guo</name_title>
    <organization>Medical Oncology of Fudan University Cancer Hospital</organization>
  </responsible_party>
  <keyword>peripheral T cell lymphoma</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>anti-angiogeneses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endostar protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

